Tele: 561.316.3330
Breaking Medical Device News

Sunday, October 17, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeImmunovia AB

Immunovia AB

U.S. Based Pancreatic Cancer Action Network Informs Members About Immunovia’s Blood Test IMMray™ PanCan-d

"The Immunovia IMMray™ PanCan-d test is an important step for some patients to be diagnosed earlier, have more treatment options and live longer", said Julie Fleshman, JD, MBA, President and CEO of Pancreatic Cancer Action Network (PanCAN).

IMMray™ PanCan-d Serum Biomarker Test Detects Early Pancreatic Cancer With 96% Accuracy: Published in Journal of Clinical Oncology

8/15/18: Mats Grahn, CEO Immunovia said: "We are delighted to see the publication of this study in JCO, which confirms that IMMray™ PanCan-d can detect pancreatic cancer in the earliest stages with an accuracy as high as 96%, in two completely different patient cohorts collected independently on different continents. "

By using this website you agree to accept Medical Device News Magazine Privacy Policy